The HIV Integrase pipeline drugs market research report outlays comprehensive information on the HIV Integrase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the HIV Integrase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Infectious Disease which include the indications Human Immunodeficiency Virus (HIV) Infections (AIDS), and Tuberculosis. It also reviews key players involved in HIV Integrase targeted therapeutics development with respective active and dormant or discontinued products.
The HIV Integrase pipeline targets constitutes close to 28 molecules. Out of which, approximately 20 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 2, 2, 8, and 3 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 5 molecule.
HIV Integrase overview
HIV integrase is the enzyme of the HIV virus that is required to integrate viral DNA into the host cellular DNA. HIV integrase is a 32kDa viral protein consisting of three domains: N-terminus, catalytic core domain, and C-terminus, which each have distinct properties and functions contributing to the efficacy of HIV integrase.
For a complete picture of HIV Integrase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.